Head and Neck Cancer Therapeutics Market Outlook 2031:
The global head and neck cancer therapeutics market size was valued at USD 1.37 Billion in 2022 and is projected to reach USD 3.95 Billion by 2031, expanding at a CAGR of 12.5% during the forecast period 2023 - 2031. The growth of the market is attributed to the growing number of cases of target diseases, increasing aging population, rising prevalence of chronic disease, healthcare initiatives by governments and various private organizations, and increasing number of diagnostic procedures.
Based on estimates from the Union for International Cancer Control (UICC), around 550,050 people were diagnosed with head and neck cancer and around 300,050 cases of deaths occur each year. Head and neck cancer is the sixth most common type of cancer. Around 90% of all head and neck cancers are squamous cell carcinomas of the head and neck (SCCHN). As compare to women, men are more affected with this type of cancer.
Currently, for head and neck cancer the standard of care includes immunotherapy, radiation therapy, chemotherapy, and surgery. Immunotherapies are expanded due to precision medicine initiative taken for managing solid malignancies based on clinical results.
Major side effects caused due to this cancer treatment are neutropenia, vomiting, bone metastasis, anemia, nausea, and pain. Rise in adoption of immunotherapy in various countries across the globe is creating an opportunity for market players to expand their presence.
Presently, around more than 43 products are going into clinical trials in the market of head and neck cancer therapeutics. Early-diagnosed cancers are curable, treatment changes based on location, type, and extent of the disease. Advancement in surgical and nonsurgical techniques is as immunotherapy and targeted therapy which helps in protecting quality of life by giving most effective care. Recent technological advancement in cancer research allows therapeutic targeting of a patient’s immune system.
Head and Neck Cancer Therapeutics Market Trends, Drivers, Restraints, and Opportunities
- Growing prevalence of head and neck cancer and increasing demand of cost-effective treatment are major responsible for driving the growth of the market over the forecast period.
- Increasing geriatric population and growing uptake of biosimilars, beneficial healthcare reforms are anticipated to fuel the expansion of the market in the coming years.
- Rising number of initiatives by government and non-governmental organizations is projected to push the market expansion during the forecast period.
- Increase in adoption of immunotherapy by various countries around the world and availability of improved healthcare are expected to boost the growth of the market.
- Technological advancement in cancer research and increasing pipeline drugs are estimated to propel the market growth in the coming years.
- High cost of products and several side effects of the treatment are major factors responsible for hampering the market growth over the forecast period.
- lack of health coverage, morbidity issues, and poor quality of life are expected to impede the growth of the market in the coming years.
Scope of Head and Neck Cancer Therapeutics Market Report
The report on the global head and neck cancer therapeutics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Head and Neck Cancer Therapeutics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Therapeutic Classes (PD Inhibitors, EGFR Inhibitors, and Microtubule Inhibitors)
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report
Bristol-Myers Squibb; Merck & Co.; Eli Lilly; Sanofi; Merck Group; Amgen; Actavis; Dr. Reddy’s Laboratories; Jiangsu Hengrui; Teva Pharmaceuticals; DFG Oncology; BioXpress Therapeutics; GE Healthcare; Philips; Siemens Healthineers; Apteryx Imaging Inc.; and Identafi
Head and Neck Cancer Therapeutics Market Segment Insights
PD inhibitors segment is projected to hold a major market share
Based on therapeutic classes, the head and neck cancer therapeutics market is divided into PD inhibitors, EGFR inhibitors, and microtubule inhibitors.
The PD inhibitors segment is expected to account for a key share of the market during the forecast period owing to launch of novel products and their increasing application in the treatment of head and neck cancer. The demand of EGFR inhibitors and microtubule inhibitors are expected to show significant decline in the coming years due to increase in adoption of immunotherapies and targeted therapies.
Key market brands are Merck’s Keytruda (pembrolizumab), Sanofi’s Taxotere (docetaxel), Bristol-Myers Squibb’s Opdivo (nivolumab), and Eli Lilly’s Erbitux (cetuximab).
North America is anticipated to dominate the market
On the basis of regions, the head and neck cancer therapeutics market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa.
The market of North America is anticipated to expand at an impressive CAGR during the forecast period. The regional market growth can be attributed to huge number of side effects related to chemotherapy and radiation therapy, increased expenditure on healthcare, rising SCCHN incidence, better government initiatives and reimbursement policies, and, development of cost-effective therapies. According to the Epidemiology and End Results (SEER) Program, in the U.S., in 2019, around 53,050 new cases of oral cavity and pharyngeal cancer were found.
On the other hand, the market of Asia Pacific is expected to exhibit a rapid growth rate in the coming years due to increasing adoption of immunotherapies. Japan is one of the highest country in the growth of adoption of immunotherapies.
The global head and neck cancer therapeutics market has been segmented on the basis of
- PD Inhibitors
- EGFR Inhibitors
- Microtubule Inhibitors
- Asia Pacific
- North America
- Latin America
- Middle East & Africa
- Bristol-Myers Squibb
- Merck & Co.
- Eli Lilly
- Merck Group
- Dr. Reddy’s Laboratories
- Jiangsu Hengrui
- Teva Pharmaceuticals
- DFG Oncology
- BioXpress Therapeutics
- GE Healthcare
- Siemens Healthineers
- Apteryx Imaging Inc.
Key players competing in the head and neck cancer therapeutics market are Bristol-Myers Squibb; Merck & Co.; Eli Lilly; Sanofi; Merck Group; Amgen; Actavis; Dr. Reddy’s Laboratories; Jiangsu Hengrui; Teva Pharmaceuticals; DFG Oncology; BioXpress Therapeutics; GE Healthcare; Philips; Siemens Healthineers; Apteryx Imaging Inc.; and Identafi.
Major market players are adopting several market strategies such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to enhance their market shares.